ClinicalTrials.gg

Program

IPX203

A development code. Also written as “CREXONT ER”, “IPX203 ER CD-LD” and “IPX203 180 mg”.

Its studies are mostly in Parkinson Disease, led by Amneal Pharmaceuticals.

Furthest: phase 4, since Dec 31, 20245 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amneal Pharmaceuticals51 open or runningphase 4since Dec 31, 2024Oct 13, 2014none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 13, 2014First study: phase 2 study in Parkinson DiseaseFirst studyNCT02271503 · 26 enrolled · United States
  2. Dec 6, 2016Phase 2 study in Advanced Parkinson's DiseaseNCT03007888 · 28 enrolled · United States
  3. Sep 12, 2018Phase 3 study in Parkinson DiseaseNCT03670953 · 630 enrolled · United States, Czechia, France and more
  4. Mar 12, 2019Phase 3 study in Parkinson DiseaseNCT03877510 · 419 enrolled · United States, Czechia, France and more
  5. Dec 31, 2024Phase 4 study in Parkinson DiseaseNCT06765668 · 220 planned · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06765668Parkinson Disease · United States4RecruitingNov 2025220
NCT03877510Parkinson Disease · United States, Czechia, France and more3CompletedMar 21, 2022419
NCT03670953Parkinson Disease · United States, Czechia, France and more3CompletedJun 15, 2021630
NCT03007888Advanced Parkinson's Disease · United States2CompletedAug 1, 201728
NCT02271503Parkinson Disease · United States2CompletedAug 201626

How it is read

Names in the registry

  • “IPX203”, 2 entries
  • “CREXONT ER”, 1 entry
  • “IPX203 ER CD-LD”, 1 entry
  • “IPX203 180 mg”, 1 entry
  • “IPX203 270 mg”, 1 entry

Codes read as this program: IPX203.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.